DEGS1 and fatty liver disease: 4-HPR has been characterised as a competitive irreversible inhibitor of Degs1 [16], which blocks ceramide accumulation in liver and skeletal muscle and reduces peripheral insulin resistance and hepatic steatosis in DIO mice [17].